Merck's anti-TL1A antibody scores a win in hidradenitis suppurativa, fails in SSc-ILD

Phase 2Mixedanti-TL1A antibodyNeutral

AI Analysis

Summary

Merck's anti-TL1A antibody from its $10.8 billion Prometheus Biosciences acquisition succeeded in a Phase 2 trial for hidradenitis suppurativa but failed in a separate Phase 2 study for systemic sclerosis-associated interstitial lung disease.

Clinical Trial Data

Phase

Outcome Details

Failed in SSc-ILD, succeeded in hidradenitis suppurativa

Importance:7/10

Sentiment:

0.00

Phase 2 datamid-stage trialmixed resultsacquisitionrare disease

Related Companies

$MRK

Read the original article

Published by Endpoints News on August 4, 2026 10:30 AM

Read Original